Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Osteoporosis Reports
Published in: Current Osteoporosis Reports 5/2015

01-10-2015 | Bone and Diabetes (AV Schwartz and P Vestergaard, Section Editors)

Diabetes and Its Effect on Bone and Fracture Healing

Authors: Hongli Jiao, E. Xiao, Dana T. Graves

Published in: Current Osteoporosis Reports | Issue 5/2015

Login to get access

Abstract

Diabetes mellitus is a metabolic disorder that increases fracture risk, interferes with bone formation, and impairs fracture healing. Type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) both increase fracture risk and have several common features that affect the bone including hyperglycemia and increased advanced glycation end product (AGE) formation, reactive oxygen species (ROS) generation, and inflammation. These factors affect both osteoblasts and osteoclasts leading to increased osteoclasts and reduced numbers of osteoblasts and bone formation. In addition to fracture healing, T1DM and T2DM impair bone formation under conditions of perturbation such as bacteria-induced periodontal bone loss by increasing osteoblast apoptosis and reducing expression of factors that stimulate osteoblasts such as BMPs and growth factors.
Literature
1.
2.
3.•
Yan W, Li X. Impact of diabetes and its treatments on skeletal diseases. Front Med. 2013;7(1):81–90. This paper discusses the impact of diabetes on skeletal diseases and shows that both T1DM and T2DM are associated with an increased risk of osteoporosis and fragility fractures. Bone mineral density is reduced in T1DM, whereas patients with T2DM have normal or slightly higher bone density, suggesting impaired bone quality is involved in T2DM.PubMedCrossRef
4.
5.
Wang Y, Zhou Y, Graves DT. FOXO transcription factors: their clinical significance and regulation. Biomed Res Int. 2014;2014:925350.PubMedCentralPubMed
6.
Yamagishi S. Role of advanced glycation end products (AGEs) in osteoporosis in diabetes. Curr Drug Targets. 2011;12(14):2096–102.PubMedCrossRef
7.
8.
Cruz NG, Sousa LP, Sousa MO, Pietrani NT, Fernandes AP, Gomes KB. The linkage between inflammation and type 2 diabetes mellitus. Diabetes Res Clin Pract. 2013;99(2):85–92.PubMedCrossRef
9.•
Nikolajczyk BS, Jagannathan-Bogdan M, Shin H, Gyurko R. State of the union between metabolism and the immune system in type 2 diabetes. Genes Immun. 2011;12(4):239–50. This paper summarizes that the cytokines secreted by multiple immune and non-immune cell types are dominant regulators of the pathological inflammation that characterizes and promotes T2D. These cytokines also be thought to contribute to diabetic complications.PubMedCrossRef
10.
Andriankaja OM, Galicia J, Dong G, Xiao W, Alawi F, Graves DT. Gene expression dynamics during diabetic periodontitis. J Dent Res. 2012;91(12):1160–5.PubMedCentralPubMedCrossRef
11.••
Pacios S, Kang J, Galicia J, et al. Diabetes aggravates periodontitis by limiting repair through enhanced inflammation. FASEB J. 2012;26(4):1423–30. This paper shows that diabetes prolongs inflammation and osteoclastogenesis in periodontitis and through TNF limits the normal reparative process by negatively modulating factors that stimulate bone formation.PubMedCentralPubMedCrossRef
12.
Pacios S, Andriankaja O, Kang J, et al. Bacterial infection increases periodontal bone loss in diabetic rats through enhanced apoptosis. Am J Pathol. 2013;183(6):1928–35.PubMedCrossRef
13.••
Alblowi J, Tian C, Siqueira MF, et al. Chemokine expression is upregulated in chondrocytes in diabetic fracture healing. Bone. 2013;53(1):294–300. This paper points to the importance of TNF-α as a mechanism for diabetes enhanced chemokine expression by chondrocytes, which may contribute to the accelerated loss of cartilage observed in diabetic fracture healing. Moreover, in vitro results of this study point to FOXO1 as a potentially important transcription factor in mediating this effect.PubMedCentralPubMedCrossRef
14.
Alblowi J, Kayal RA, Siqueria M, et al. High levels of tumor necrosis factor-alpha contribute to accelerated loss of cartilage in diabetic fracture healing. Am J Pathol. 2009;175(4):1574–85.PubMedCentralPubMedCrossRef
15.
Silva JA, Lopes Ferrucci D, Peroni LA, et al. Periodontal disease-associated compensatory expression of osteoprotegerin is lost in type 1 diabetes mellitus and correlates with alveolar bone destruction by regulating osteoclastogenesis. Cells Tissues Organs. 2012;196(2):137–50.PubMedCrossRef
16.
Silva JA, Ferrucci DL, Peroni LA, et al. Sequential IL-23 and IL-17 and increased Mmp8 and Mmp14 expression characterize the progression of an experimental model of periodontal disease in type 1 diabetes. J Cell Physiol. 2012;227(6):2441–50.PubMedCrossRef
17.
Kang J, de Brito BB, Pacios S, et al. Aggregatibacter actinomycetemcomitans infection enhances apoptosis in vivo through a caspase-3-dependent mechanism in experimental periodontitis. Infect Immun. 2012;80(6):2247–56.PubMedCentralPubMedCrossRef
18.
Liu R, Bal HS, Desta T, et al. Diabetes enhances periodontal bone loss through enhanced resorption and diminished bone formation. J Dent Res. 2006;85(6):510–4.PubMedCentralPubMedCrossRef
19.
Bastos AS, Graves DT, Loureiro AP, et al. Lipid peroxidation is associated with the severity of periodontal disease and local inflammatory markers in patients with type 2 diabetes. J Clin Endocrinol Metab. 2012;97:1353–62.CrossRef
20.
Duarte PM, de Oliveira MC, Tambeli CH, Parada CA, Casati MZ, Nociti Jr FH. Overexpression of interleukin-1beta and interleukin-6 may play an important role in periodontal breakdown in type 2 diabetic patients. J Periodontal Res. 2007;42(4):377–81.PubMedCrossRef
21.
Mahamed DA, Marleau A, Alnaeeli M, et al. G(−) anaerobes-reactive CD4 + T-cells trigger RANKL-mediated enhanced alveolar bone loss in diabetic NOD mice. Diabetes. 2005;54(5):1477–86.PubMedCrossRef
22.
Santos VR, Lima JA, Goncalves TE, et al. Receptor activator of nuclear factor-kappa B ligand/osteoprotegerin ratio in sites of chronic periodontitis of subjects with poorly and well-controlled type 2 diabetes. J Periodontol. 2010;81(10):1455–65.PubMedCrossRef
23.
Drosatos-Tampakaki Z, Drosatos K, Siegelin Y, et al. Palmitic acid and DGAT1 deficiency enhance osteoclastogenesis, while oleic acid-induced triglyceride formation prevents it. J Bone Miner Res. 2014;29(5):1183–95.PubMedCrossRef
24.
Hasturk H, Kantarci A, Goguet-Surmenian E, et al. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J Immunol. 2007;179(10):7021–9.PubMedCrossRef
25.
Sarkar PD, Choudhury AB. Relationships between serum osteocalcin levels versus blood glucose, insulin resistance and markers of systemic inflammation in central Indian type 2 diabetic patients. Eur Rev Med Pharmacol Sci. 2013;17(12):1631–5.PubMed
26.
27.
Lu H, Kraut D, Gerstenfeld L, Graves D. Diabetes interferes with the bone formation by affecting the expression of transcription factors that regulate osteoblast differentiation. Endocrinology. 2003;144:346–52.PubMedCrossRef
28.••
Coe LM, Irwin R, Lippner D, McCabe LR. The bone marrow microenvironment contributes to type I diabetes induced osteoblast death. J Cell Physiol. 2011;226(2):477–83. The findings in this paper implicate the bone marrow microenvironment and TNF-α in mediating osteoblast death and contributing to type I diabetic bone loss.PubMedCrossRef
29.
Vlassara H, Striker GE. Advanced glycation endproducts in diabetes and diabetic complications. Endocrinol Metab Clin N Am. 2013;42(4):697–719.CrossRef
30.
Xie J, Mendez JD, Mendez-Valenzuela V, Aguilar-Hernandez MM. Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell Signal. 2013;25(11):2185–97.PubMedCrossRef
31.
Catalfamo DL, Britten TM, Storch DL, Calderon NL, Sorenson HL, Wallet SM. Hyperglycemia induced and intrinsic alterations in type 2 diabetes-derived osteoclast function. Oral Dis. 2013;19(3):303–12.PubMedCentralPubMed
32.
Miyata T, Kawai R, Taketomi S, Sprague SM. Possible involvement of advanced glycation end-products in bone resorption. Nephrol Dial Transplant Off Publ Eur Dial Transplant Assoc Eur Ren Assoc. 1996;11 Suppl 5:54–7.
33.
Ding KH, Wang ZZ, Hamrick MW, et al. Disordered osteoclast formation in RAGE-deficient mouse establishes an essential role for RAGE in diabetes related bone loss. Biochem Biophys Res Commun. 2006;340(4):1091–7.PubMedCrossRef
34.
Lalla E, Lamster IB, Feit M, et al. Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Clin Invest. 2000;105(8):1117–24.PubMedCentralPubMedCrossRef
35.
Lamster IB. Diabetes and oral health. What’s their relationship? Diabetes Self Manag. 2012;29(3):30. 32–34.PubMed
36.
Sanguineti R, Storace D, Monacelli F, Federici A, Odetti P. Pentosidine effects on human osteoblasts in vitro. Ann N Y Acad Sci. 2008;1126:166–72.PubMedCrossRef
37.
Alikhani M, Alikhani Z, Boyd C, et al. Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone. 2007;40(2):345–53.PubMedCentralPubMedCrossRef
38.
Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 1999;48(1):1–9.PubMedCrossRef
39.
Dandona P, Thusu K, Cook S, et al. Oxidative damage to DNA in diabetes mellitus. Lancet. 1996;347(8999):444–5.PubMedCrossRef
40.
41.
42.
Niedowicz DM, Daleke DL. The role of oxidative stress in diabetic complications. Cell Biochem Biophys. 2005;43(2):289–330.PubMedCrossRef
43.
Sakurai T, Tsuchiya S. Superoxide production from nonenzymatically glycated protein. FEBS Lett. 1988;236(2):406–10.PubMedCrossRef
44.
Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol. 2003;91(3A):7A–11A.PubMedCrossRef
45.
Mohazzab KM, Kaminski PM, Wolin MS. NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am J Physiol. 1994;266(6 Pt 2):H2568–72.PubMed
46.•
Morikawa D, Norikawa D, Nojiri H, et al. Cytoplasmic reactive oxygen species and SOD1 regulate bone mass during mechanical unloading. J Bone Miner Res. 2013;28(11):2368–80. The results of this paper indicate that mechanical unloading, in part, regulates bone mass via intracellular ROS generation and the Sod1 expression, suggesting that activating Sod1 may be a preventive strategy for ameliorating mechanical unloading-induced bone loss.PubMedCrossRef
47.
Omori K, Ohira T, Uchida Y, et al. Priming of neutrophil oxidative burst in diabetes requires preassembly of the NADPH oxidase. J Leukoc Biol. 2008;84(1):292–301.PubMedCentralPubMedCrossRef
48.
Ha H, Kwak HB, Lee SW, et al. Reactive oxygen species mediate RANK signaling in osteoclasts. Exp Cell Res. 2004;301(2):119–27.PubMedCrossRef
49.
Yao D, Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes. 2010;59(1):249–55.PubMedCentralPubMedCrossRef
50.•
Bartell SM, Kim HN, Ambrogini E, et al. FoxO proteins restrain osteoclastogenesis and bone resorption by attenuating H2O2 accumulation. Nat Commun. 2014;5:3773. This paper shows that intracellular H2O2 accumulation is a critical and purposeful adaptation for the differentiation and survival of osteoclasts and this is achieved, at least in part, by downregulating the H2O2-inactivating enzyme catalase. Catalase downregulation results from the repression of the transcriptional activity of FoxO1, 3 and 4 by RANKL, the indispensable signal for the generation of osteoclasts, via an Akt-mediated mechanism.PubMedCentralPubMedCrossRef
51.
Wang Y, Dong G, Jeon HH, et al. FOXO1 mediates RANKL-induced osteoclast formation and activity. J Immunol. 2015;194(6):2878–87.PubMedCrossRef
52.
Almeida M, O’Brien CA. Basic biology of skeletal aging: role of stress response pathways. J Gerontol A: Biol Med Sci. 2013;68(10):1197–208.CrossRef
53.
Fraser JH, Helfrich MH, Wallace HM, Ralston SH. Hydrogen peroxide, but not superoxide, stimulates bone resorption in mouse calvariae. Bone. 1996;19(3):223–6.PubMedCrossRef
54.••
Garcia-Hernandez A, Arzate H, Gil-Chavarria I, Rojo R, Moreno-Fierros L. High glucose concentrations alter the biomineralization process in human osteoblastic cells. Bone. 2012;50(1):276–88. This paper shows that a high concentration of extracellular glucose probably acts as an endogenous factor that alters biomineralization. It also suggests that in osteoblastic cells, high glucose regulates the expression of proinflammatory cytokines by crosstalk between signaling pathways, such as PKC-MAPK with ROS or increased AGEs and RAGEs.PubMedCrossRef
55.
Bai XC, Lu D, Bai J, et al. Oxidative stress inhibits osteoblastic differentiation of bone cells by ERK and NF-kappaB. Biochem Biophys Res Commun. 2004;314(1):197–207.PubMedCrossRef
56.
McCarthy AD, Etcheverry SB, Bruzzone L, Lettieri G, Barrio DA, Cortizo AM. Non-enzymatic glycosylation of a type I collagen matrix: effects on osteoblastic development and oxidative stress. BMC Cell Biol. 2001;2:16.PubMedCentralPubMedCrossRef
57.
Lechleitner M, Koch T, Herold M, Dzien A, Hoppichler F. Tumour necrosis factor-alpha plasma level in patients with type 1 diabetes mellitus and its association with glycaemic control and cardiovascular risk factors. J Intern Med. 2000;248(1):67–76.PubMedCrossRef
58.
Gonzalez Y, Herrera MT, Soldevila G, et al. High glucose concentrations induce TNF-alpha production through the down-regulation of CD33 in primary human monocytes. BMC Immunol. 2012;13:19.PubMedCentralPubMedCrossRef
59.
Wu YY, Yu T, Zhang XH, et al. 1,25(OH)2D3 inhibits the deleterious effects induced by high glucose on osteoblasts through undercarboxylated osteocalcin and insulin signaling. J Steroid Biochem Mol Biol. 2012;132(1–2):112–9.PubMedCrossRef
60.
Ogawa N, Yamaguchi T, Yano S, Yamauchi M, Yamamoto M, Sugimoto T. The combination of high glucose and advanced glycation end-products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced increase in the receptor for AGEs. Horm Metab Res. 2007;39(12):871–5.PubMedCrossRef
61.
Gopalakrishnan V, Vignesh RC, Arunakaran J, Aruldhas MM, Srinivasan N. Effects of glucose and its modulation by insulin and estradiol on BMSC differentiation into osteoblastic lineages. Biochem Cell Biol. 2006;84(1):93–101.PubMedCrossRef
62.
Lecka-Czernik B, Gubrij I, Moerman EJ, et al. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J Cell Biochem. 1999;74(3):357–71.PubMedCrossRef
63.
Thomas DM, Hards DK, Rogers SD, Ng KW, Best JD. Insulin receptor expression in bone. J Bone Miner Res. 1996;11(9):1312–20.PubMedCrossRef
64.
Thrailkill KM, Lumpkin Jr CK, Bunn RC, Kemp SF, Fowlkes JL. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab. 2005;289(5):E735–45.PubMedCentralPubMedCrossRef
65.
Gandhi A, Beam HA, O’Connor JP, Parsons JR, Lin SS. The effects of local insulin delivery on diabetic fracture healing. Bone. 2005;37(4):482–90.PubMedCrossRef
66.•
Nyman JS, Even JL, Jo CH, et al. Increasing duration of type 1 diabetes perturbs the strength-structure relationship and increases brittleness of bone. Bone. 2011;48(4):733–40. This paper shows that in a mouse model of T1DM, systemic insulin deficiency thus the lack of insulin signaling in osteoblasts can affect bone formation and architecture, thereby increasing risk of fracture.PubMedCentralPubMedCrossRef
67.
Valerio G, del Puente A, Esposito-del Puente A, Buono P, Mozzillo E, Franzese A. The lumbar bone mineral density is affected by long-term poor metabolic control in adolescents with type 1 diabetes mellitus. Horm Res. 2002;58(6):266–72.PubMedCrossRef
68.
Rakel A, Sheehy O, Rahme E, LeLorier J. Osteoporosis among patients with type 1 and type 2 diabetes. Diabetes Metab. 2008;34(3):193–205.PubMedCrossRef
69.
Iida-Klein A, Hahn TJ. Insulin acutely suppresses parathyroid hormone second messenger generation in UMR-106-01 osteoblast-like cells: differential effects on phospholipase C and adenylate cyclase activation. Endocrinology. 1991;129(2):1016–24.PubMedCrossRef
70.
Iida-Klein A, Varlotta V, Hahn TJ. Protein kinase C activity in UMR-106-01 cells: effects of parathyroid hormone and insulin. J Bone Miner Res. 1989;4(5):767–74.PubMedCrossRef
71.
Janghorbani M, Feskanich D, Willett WC, Hu F. Prospective study of diabetes and risk of hip fracture: the Nurses’ Health Study. Diabetes Care. 2006;29(7):1573–8.PubMedCrossRef
72.
Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166(5):495–505.PubMedCrossRef
73.
Moyer-Mileur LJ, Slater H, Jordan KC, Murray MA. IGF-1 and IGF-binding proteins and bone mass, geometry, and strength: relation to metabolic control in adolescent girls with type 1 diabetes. J Bone Miner Res. 2008;23(12):1884–91.PubMedCentralPubMedCrossRef
74.
Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int J Established Results Cooperation Between Eur Found Osteoporos Natl Osteoporos Found USA. 2007;18(4):427–44.CrossRef
75.
Ai-Aql ZS, Alagl AS, Graves DT, Gerstenfeld LC, Einhorn TA. Molecular mechanisms controlling bone formation during fracture healing and distraction osteogenesis. J Dent Res. 2008;87(2):107–18.PubMedCentralPubMedCrossRef
76.
Gerstenfeld LC, Wronski TJ, Hollinger JO, Einhorn TA. Application of histomorphometric methods to the study of bone repair. J Bone Miner Res. 2005;20(10):1715–22.PubMedCrossRef
77.
Gerstenfeld LC, Cho TJ, Kon T, et al. Impaired fracture healing in the absence of TNF-alpha signaling: the role of TNF-alpha in endochondral cartilage resorption. J Bone Miner Res. 2003;18(9):1584–92.PubMedCrossRef
78.
Follak N, Kloting I, Merk H. Influence of diabetic metabolic state on fracture healing in spontaneously diabetic rats. Diabetes Metab Res Rev. 2005;21(3):288–96.PubMedCrossRef
79.
Kawaguchi H, Kurokawa T, Hanada K, et al. Stimulation of fracture repair by recombination human basic fibroblast growth factor in normal and streptozotocin-diabetic rats. Endocrinology. 1994;135:774–81.PubMed
80.
Loder RT. The influence of diabetes mellitus on the healing of closed fractures. Clin Orthop Relat Res. 1988;232:210–6.PubMed
81.
Folk JW, Starr AJ, Early JS. Early wound complications of operative treatment of calcaneus fractures: analysis of 190 fractures. J Orthop Trauma. 1999;13(5):369–72.PubMedCrossRef
82.
Retzepi M, Donos N. The effect of diabetes mellitus on osseous healing. Clin Oral Implants Res. 2010;21(7):673–81.PubMedCrossRef
83.
Ketenjian AY, Jafri AM, Arsenis C. Studies on the mechanism of callus cartilage differentiation and calcification during fracture healing. Orthop Clin N Am. 1978;9(1):43–65.
84.
Kayal RA, Siqueira M, Alblowi J, et al. TNF-alpha mediates diabetes-enhanced chondrocyte apoptosis during fracture healing and stimulates chondrocyte apoptosis through FOXO1. J Bone Miner Res. 2010;25(7):1604–15.PubMedCentralPubMedCrossRef
85.•
Bahney CS, Hu DP, Miclau 3rd T, Marcucio RS. The multifaceted role of the vasculature in endochondral fracture repair. Front Endocrinol. 2015;6:4. This paper discusses the multifaceted role of the vasculature during fracture repair and shows that alterations in vascularization can affect the transition from cartilage to bone during fracture repair.CrossRef
86.
Botushanov NP, Orbetzova MM. Bone mineral density and fracture risk in patients with type 1 and type 2 diabetes mellitus. Folia Med. 2009;51(4):12–7.
87.
Stolzing A, Sellers D, Llewelyn O, Scutt A. Diabetes induced changes in rat mesenchymal stem cells. Cells Tissues Organs. 2010;191(6):453–65.PubMedCrossRef
88.
Sheweita SA, Khoshhal KI. Calcium metabolism and oxidative stress in bone fractures: role of antioxidants. Curr Drug Metab. 2007;8(5):519–25.PubMedCrossRef
89.
90.
Vashishth D, Gibson GJ, Khoury JI, Schaffler MB, Kimura J, Fyhrie DP. Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone. 2001;28(2):195–201.PubMedCrossRef
91.•
Tang SY, Vashishth D. Non-enzymatic glycation alters microdamage formation in human cancellous bone. Bone. 2010;46(1):148–54. By using a novel microCT technique to characterize and quantify microdamage, this study shows that the accumulation of AGEs in the bone matrix significantly alters the quantity and morphology of microdamage production and results in reduced fracture resistance.PubMedCentralPubMedCrossRef
92.•
Tang SY, Vashishth D. The relative contributions of non-enzymatic glycation and cortical porosity on the fracture toughness of aging bone. J Biomech. 2011;44(2):330–6. The paper investigates the contribution of AGEs on the fracture toughness of human bone and finds that they cause a 52 % reduction in propagation fracture toughness.PubMedCentralPubMedCrossRef
93.•
Okazaki K, Yamaguchi T, Tanaka K, et al. Advanced glycation end products (AGEs), but not high glucose, inhibit the osteoblastic differentiation of mouse stromal ST2 cells through the suppression of osterix expression, and inhibit cell growth and increasing cell apoptosis. Calcif Tissue Int. 2012;91(4):286–96. This paper suggests that AGEs may inhibit the osteoblastic differentiation of stromal cells by decreasing osterix expression and partly by increasing RAGE expression, as well as inhibiting cell growth and increasing cell apoptosis.PubMedCrossRef
94.
Rosen DM, Luben RA. Multiple hormonal mechanisms for the control of collagen synthesis in an osteoblast-like cell line, MMB-1. Endocrinology. 1983;112(3):992–9.PubMedCrossRef
95.
Hill PA, Tumber A, Meikle MC. Multiple extracellular signals promote osteoblast survival and apoptosis. Endocrinology. 1997;138(9):3849–58.PubMed
96.
Shukunami C, Ishizeki K, Atsumi T, Ohta Y, Suzuki F, Hiraki Y. Cellular hypertrophy and calcification of embryonal carcinoma-derived chondrogenic cell line ATDC5 in vitro. J Bone Miner Res. 1997;12(8):1174–88.PubMedCrossRef
97.
Iwata K, Asawa Y, Fujihara Y, et al. The effects of rapid- or intermediate-acting insulin on the proliferation and differentiation of cultured chondrocytes. Curr Aging Sci. 2010;3(1):26–33.PubMedCrossRef
98.
Watford M, Mapes RE. Hormonal and acid–base regulation of phosphoenolpyruvate carboxykinase mRNA levels in rat kidney. Arch Biochem Biophys. 1990;282(2):399–403.PubMedCrossRef
99.
Fujii H, Hamada Y, Fukagawa M. Bone formation in spontaneously diabetic Torii—newly established model of non-obese type 2 diabetes rats. Bone. 2008;42(2):372–9.PubMedCrossRef
100.
Hamada Y, Kitazawa S, Kitazawa R, Fujii H, Kasuga M, Fukagawa M. Histomorphometric analysis of diabetic osteopenia in streptozotocin-induced diabetic mice: a possible role of oxidative stress. Bone. 2007;40(5):1408–14.PubMedCrossRef
101.
Kayal RA, Alblowi J, McKenzie E, et al. Diabetes causes the accelerated loss of cartilage during fracture repair which is reversed by insulin treatment. Bone. 2009;44(2):357–63.PubMedCentralPubMedCrossRef
102.
Dedania J, Borzio R, Paglia D, et al. Role of local insulin augmentation upon allograft incorporation in a rat femoral defect model. J Orthop Res Off Publ Orthop Res Soc. 2011;29(1):92–9.CrossRef
103.
Paglia DN, Wey A, Breitbart EA, et al. Effects of local insulin delivery on subperiosteal angiogenesis and mineralized tissue formation during fracture healing. J Orthop Res. 2013;31(5):783–91.PubMedCrossRef
104.
Ackermann PW, Hart DA. Influence of comorbidities: neuropathy, vasculopathy, and diabetes on healing response quality. Adv Wound Care. 2013;2(8):410–21.CrossRef
105.
106.•
Zhang C, Ponugoti B, Tian C, Xu F, Tarapore R, Batres A, et al. FOXO1 differentially regulates both normal and diabetic wound healing. J Cell Biol. 2015;209(2):289–303. The manuscript demonstrates that the transcription factor FOXO1 switches from inducing a pro- wound response an anti-healing transcription factor when cells are exposed to high glucose. It provides an epigenetic explanation for diabetes-impaired healing.PubMedPubMedCentralCrossRef
Metadata
Title
Diabetes and Its Effect on Bone and Fracture Healing
Authors
Hongli Jiao
E. Xiao
Dana T. Graves
Publication date
01-10-2015
Publisher
Springer US
Published in
Current Osteoporosis Reports / Issue 5/2015
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-015-0286-8

Other articles of this Issue 5/2015

Current Osteoporosis Reports 5/2015 Go to the issue

Nutrition, Exercise, and Lifestyle in Osteoporosis (CM Weaver and R Daly, Section Editors)

Sarcopenia and the Common Mental Disorders: a Potential Regulatory Role of Skeletal Muscle on Brain Function?

Skeletal Development (E Schipani and E Zelzer, Section Editors)

Notochord to Nucleus Pulposus Transition

Muscle and Bone (L Bonewald and M Hamrick, Section Editors)

Muscle-Bone Crosstalk in Amyotrophic Lateral Sclerosis

Therapeutics and Medical Management (E Shane and R Adler, Section Editors)

Bone Imaging and Fracture Risk after Spinal Cord Injury

Nutrition, Exercise, and Lifestyle in Osteoporosis (CM Weaver and R Daly, Section Editors)

The Microbiome and Osteosarcopenic Obesity in Older Individuals in Long-Term Care Facilities

Skeletal Development (E Schipani and E Zelzer, Section Editors)

Pluripotent Stem Cells and Skeletal Regeneration—Promise and Potential